Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia

Panagiotis Alexopoulos^{1

2}, Nathalie Thierjung¹, Polychronis Economou³, Lukas Werle^{1

4}, Felix Buhl¹, Simone Kagerbauer⁵, Anastasios D Papanastasiou⁶, Timo Grimmer¹, Philippos Gourzis², Achim Berthele⁷, Bernhard Hemmer^{7

8}, Hubert Kübler⁹, Jan Martin⁵, Antonios Politis^{10

11}, Robert Perneczky^{8

12

13

14}

Affiliations

¹ Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
² Department of Psychiatry, University Hospital of Rion, University of Patras, Patras, Greece.
³ Department of Civil Engineering (Statistics), University of Patras, Patras, Greece.
⁴ Max Planck Institute of Psychiatry, Munich, Germany.
⁵ Department of Anaesthesiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
⁶ Molecular Oncology Laboratory, Division of Oncology, University Hospital of Patras, University of Patras, Patras, Greece.
⁷ Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
⁸ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
⁹ Department of Urology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
¹⁰ First Department of Psychiatry, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
¹¹ Department of Psychiatry, Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins Medical School, Baltimore, USA.
¹² Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany.
¹³ Ageing Epidemiology (AGE) Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, UK.
¹⁴ German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.

PMID: 30909232
DOI: 10.3233/JAD-181088

Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia

Panagiotis Alexopoulos et al. J Alzheimers Dis. 2019.

. 2019;69(1):83-90.

doi: 10.3233/JAD-181088.

Authors

Affiliations

¹ Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
² Department of Psychiatry, University Hospital of Rion, University of Patras, Patras, Greece.
³ Department of Civil Engineering (Statistics), University of Patras, Patras, Greece.
⁴ Max Planck Institute of Psychiatry, Munich, Germany.
⁵ Department of Anaesthesiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
⁶ Molecular Oncology Laboratory, Division of Oncology, University Hospital of Patras, University of Patras, Patras, Greece.
⁷ Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
⁸ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
⁹ Department of Urology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
¹⁰ First Department of Psychiatry, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
¹¹ Department of Psychiatry, Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins Medical School, Baltimore, USA.
¹² Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany.
¹³ Ageing Epidemiology (AGE) Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, UK.
¹⁴ German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.

PMID: 30909232
DOI: 10.3233/JAD-181088

Abstract

Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N = 33) are significantly lower (p < 0.01) than those of cognitively healthy elderly individuals without AD (N = 39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate.

Keywords: Biomarker candidate; NIA-AA research framework diagnostic criteria; soluble amyloid-β protein precursor β.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia

Affiliations

Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical